Clinical and laboratory features of newly diagnosed multiple myeloma: A retrospective, single-centre analysis

Chinese Medical Journal

Volumn 120, Issue 19, 2007, Pages 1727-1729

  Mai, Yu Jie ^a,b   Qi, Pei Jing ^a   Xu, Yan ^a   Zou, De Hui ^a   Wang, Ya Fei ^a   Zhao, Yao Zhong ^a   Yang, Ren Chi ^a   Xiao, Zhi Jian ^a   Qiu, Lu Gui ^a  

^a INSTITUTE OF HEMATOLOGY AND BLOOD DISEASES HOSPITAL   (China)

^b DALIAN UNIVERSITY   (China)

Author keywords

Diagnosis; Multiple myeloma; Survival

Indexed keywords

ALBUMIN; BETA 2 MICROGLOBULIN; C REACTIVE PROTEIN; CALCIUM; CREATININE; HEMOGLOBIN; LACTATE DEHYDROGENASE; M PROTEIN;

ADULT; AGED; ANEMIA; ARTICLE; BLEEDING; BLOOD CELL COUNT; BLURRED VISION; BONE MARROW BIOPSY; BONE PAIN; CLINICAL FEATURE; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE COURSE; EDEMA; FATIGUE; FEMALE; FEVER; HUMAN; HUMAN TISSUE; LABORATORY TEST; LEUKOCYTOSIS; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; PROGNOSIS; PROTEIN ELECTROPHORESIS; RASH; RETROSPECTIVE STUDY; SURVIVAL; THROMBOCYTE COUNT; THROMBOCYTOPENIA; THROMBOCYTOSIS;

EID: 35348936787     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: 10.1097/00029330-200710010-00018     Document Type: Article

References (10)

1. Kyle RA, Gertz MA, Witzig TE, Lust JA, Lacy MQ, Dispenzieri A, et al. Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc 2003; 78: 21-33.
2. Riccardi A, Gobbi PG, Ucci G, Bertoloni D, Luoni R, Rutigliano L, et al. Changing clinical presentation of multiple myeloma. Eur J Cancer 1991; 27: 1401-1405.
3. Zhang ZN, Shen Ti. The criteria of diagnosis and treatment effect for hematological diseases. 2nd ed. Beijing: Beijing Science Press; 1998: 373-380.
4. Tao ZF, Fu WJ, Chen YB, Yuan ZG, Wang DX, Hou J. Prognostic analysis and assessment on the clinical staging systems of multiple myeloma: a report of 206 cases. Chin J Cancer 2006; 25: 461-464.
5. Wu YJ, Li HP, Zhang ZN. Clinical analysis of 125 patients with multiple myeloma. Natl Med J China (Chin) 1992; 13: 349-351.
6. Greipp PR, Leong T, Bennett JM, Gaillard JP, Klein B, Stewart JA, et al. Plasmablastic morphology - an independent prognostic factor with clinical and laboratory correlates: Eastern Cooperative Oncology Group (ECOG) Myeloma Trial E9486 report by the ECOG myeloma laboratory group. Blood 1998; 91: 2501-2507.
7. Cuzick J, De Stavola BL, Cooper EH, Chapman C, Mac Lennan IC. Long-term prognostic value of serum β2-microglobulin in myelomatosis. Br J Haematol 1990; 75: 506-510.
8. Jacobson JL, Hussein MA, Barlogie B, Durie BGM, Crowley JJ. A new staging system for multiple myeloma patients based on the Southwest Oncology Group (SWOG) experience. Br J Haematol 2003; 122: 441-450.
9. Greipp PR, Miguel JS, Durie BG, Crowley JJ, Barlogie B, Blade J, et al. International staging system for multiple myeloma. J Clin Oncol 2005; 23: 3412-3420.
10. Mihou D, Katodritou I, Zervas K. Evaluation of five staging systems in 470 patients with multiple myeloma. Haematologica 2006; 91: 1149-1150.